<DOC>
	<DOC>NCT02483585</DOC>
	<brief_summary>A Phase 3, Randomized, Double-blind, Placebo-controlled Study followed by open-label treatment phase. To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with episodic migraine</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of AMG 334 Compared to Placebo in Migraine Prevention</brief_title>
	<detailed_description>A Phase 3, Randomized, Double-blind, Placebo-controlled Study followed by open-label treatment phase. Adults with a history of migraine with or without aura for ≥ 12 months and who experience ≥ 4 to &lt; 15 migraine days per month with &lt; 15 headache days per month will be randomized 1:1 to placebo or AMG 334. Double-blind AMG 334 or placebo will be administered during the 12-week double-blind treatment phase and open-label AMG 334 will be administered during the 28-week open-label treatment phase. Investigational product doses are fixed and will not be adjusted for individual subjects during the study.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History of Migraines High migraine frequency Demonstrated compliance with the eDiary Older than 50 years of age at migraine onset. History of cluster headache or hemiplegic migraine headache. Unable to differentiate migraine from other headaches No therapeutic response with &gt; 2 categories for prophylactic treatment of migraine after an adequate therapeutic trial. Concomitant use of 2 or more medications with possible migraine prophylactic effects within 2 months prior to the start of the baseline phase or during the baseline phase. If only 1 prophylactic medication is used, the dose must be stable within 2 months prior to the start of the baseline phase and throughout the study Used a prohibited medication, device, or procedure within 2 months prior to the start of the baseline phase or during the baseline phase. Received botulinum toxin Anticipated to require any excluded medication, device, or procedure during the study. Active chronic pain syndromes (such as fibromyalgia and chronic pelvic pain). History of major psychiatric disorder. History of seizure disorder or other significant neurological conditions other than migraine. Human immunodeficiency virus (HIV) infection by history. Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina, or coronary artery bypass surgery or other revascularization procedure within 12 months prior to screening. The subject is at risk of selfharm or harm to others. Previously randomized into an AMG 334 study. Unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Episodic</keyword>
	<keyword>Prevention</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>